Universal Time: 22:17  |  Local Time: 22:17 (0h GMT)
Select your timezone:

N8 - Zoom Virtual Networking Room
Tacrolimus as the induction agent for low risk kidney transplant leads to comparable graft and patient outcomes and low incidence of infections

Monday September 14, 2020 | 14:30 to 15:15
Room: Networking 5
Track: N/A

Video is available - Log in to view. You must be registered to the event to view content

Description

The risk of fatal infection and immunosuppression induced complications is higher in patients in countries like India. Tacrolimus is used as an induction agent , by starting Tacrolimus induction 2 days prior to living donor kidney transplant for related cases. When compared with patients given standard induction therapies, patients with tacrolimus induction had very less incidence of infections 1 year post transplant. Though the risk of tacrolimus induced AKI was also seen in a few cases with Tacrolimus induced patients, when compared with the risk of infections and incidence of life threatening infections needing ICU, AKI incidence due to tacrolimus were less and reversible. We propose a networking session to discuss our experience and have an open session with experts from similar country zones and rest of the world to have their inputs and debate whether we need to consider lowering the induction immunosuppression for living donor kidney transplant patients? Tacrolimus is used as an induction agent , by starting Tacrolimus induction 2 days prior to living donor kidney transplant for related cases. When compared with patients given standard induction therapies, patients with tacrolimus induction had very less incidence of infections 1 year post transplant. Though the risk of tacrolimus induced AKI was also seen in a few cases with Tacrolimus induced patients, when compared with the risk of infections and incidence of life threatening infections needing ICU, AKI incidence due to tacrolimus were less and reversible. We propose a networking session to discuss our experience and have an open session with experts from similar country zones and rest of the world to have their inputs and debate whether we need to consider lowering the induction immunosuppression for living donor kidney transplant patients?

Presentations

Dr. Tushar Dighe, India
Moderator

Anita K. Patel, United States
Panelist

Dr. Atul Mulay, India
Panelist

Ask a question or make a comment
This will appear in the session question feed in the dashboard

There are no comments yet...

WebApp Sponsor

© 2020 TTS 2020